Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:TEVA
Previous Symbol
CUSIPN/A
Phone972-3926-7267
Debt
Debt-to-Equity Ratio1.75
Current Ratio0.94
Quick Ratio0.61
Price-To-Earnings
Trailing P/E Ratio5.60
Forward P/E Ratio7.80
P/E Growth6.63
Sales & Book Value
Annual Sales$22.39 billion
Price / Sales1.00
Cash Flow$6.2528 per share
Price / Cash3.52
Book Value$15.06 per share
Price / Book1.46
Profitability
EPS (Most Recent Fiscal Year)$3.93
Net Income$-16,265,000,000.00
Net Margins-54.67%
Return on Equity21.83%
Return on Assets5.01%
Miscellaneous
Employees51,792
Outstanding Shares1,016,880,000
Market Cap$22.37 billion
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its earnings results on Thursday, November, 1st. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.11. The firm earned $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. Teva Pharmaceutical Industries's revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period last year, the firm posted $1.00 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of $2.80-2.95 for the period, compared to the Thomson Reuters consensus estimate of $2.78. The company issued revenue guidance of $18.6-19.0 billion, compared to the consensus revenue estimate of $18.85 billion.Teva Pharmaceutical Industries also updated its FY 2018 guidance to $2.80-2.95 EPS.
What price target have analysts set for TEVA?
22 Wall Street analysts have issued twelve-month price targets for Teva Pharmaceutical Industries' stock. Their forecasts range from $11.00 to $30.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $22.2105 in the next year. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 2 sell ratings, 15 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
- 2. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (9/27/2018)
- 3. Mizuho analysts commented, "We lowered 2018 estimates due to weaker but note that stronger Copaxone and EpiPen could make up the difference. We reiterate our Buy rating and $28 PT, but have become more cautious on a timely migraine approval on Sept 16. We see shares as undervalued even if approval is delayed." (8/24/2018)
- 4. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth. After declining sharply in 2017, Teva’s shares have also picked up this year. Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and aims to cut its global workforce by more than 25% over the next two years. Teva expects to save almost $3 billion by the end of 2019 from these initiatives. Its financial position seems more stable than before as it is regularly paying down debt." (7/9/2018)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
News headlines about TEVA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Bristol-Myers Squibb (BMY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Jazz Pharmaceuticals (JAZZ) and Perrigo (PRGO).
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 57)
- Mr. Michael McClellan, Exec. VP & CFO (Age 47)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.69%), Franklin Resources Inc. (6.54%), FMR LLC (2.41%), Abrams Capital Management L.P. (1.92%), Polaris Capital Management LLC (0.97%) and Alliancebernstein L.P. (0.93%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which institutional investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Northern Cross LLC, Franklin Resources Inc., Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, Renaissance Technologies LLC, Schroder Investment Management Group, Teachers Advisors LLC and Tobam. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which institutional investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Beck Mack & Oliver LLC, Alliancebernstein L.P., Mckinley Capital Management LLC Delaware, Clal Insurance Enterprises Holdings Ltd, Harel Insurance Investments & Financial Services Ltd., BlueMountain Capital Management LLC and Polaris Capital Management LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $22.01.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $22.37 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
